Erwinaze is the brand name for Erwinia asparaginase, a drug closely related to PEG l-asparaginase (PEG). Unlike PEG, Erwinaze is generally administered as an intra-muscular shot (for instance, in the thigh), and is usually given more frequently than the equivalent dose of PEG.
Erwinaze has been in a state of nearly constant shortage for years, so it is generally only used when the patient has an allergic reaction to PEG. While the shortage is real, most patients are able to get the doses they need with some infrequent delays. A change in the ordering process in 2019 sought to even out some of the supply issues, and a major change to the partnership between its producer and distributor may mark a major improvement in 2020 and beyond.
- Erwinaze supply – follow Erwinia supply changes and sign up for notifications as supply changes occur
- Saving Ava: A mother refuses to accept shortage of cancer drug
- Erwinaze (asparaginase Erwinia chrysanthemi)